Ibrutinib oral suspension bioavailability and compatibility for optimal enteral administration route
Jonas Paludo, Lisa Nodzon, Xavier Woot de Trixhe, Michelle Pacia, Heena Mavani, Harisha Atluri, Thomas J Huemann, Jessica Shelly, Yemin Liu, Shayna Sarosiek · 2025
Read Ibrutinib oral suspension bioavailability and compatibility for optimal enteral administration route by Jonas Paludo, Lisa Nodzon, Xavier Woot de Trixhe, Michelle Pacia, Heena Mavani, Harisha Atluri, Thomas J Huemann, Jessica Shelly, Yemin Liu, Shayna Sarosiek (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12743846.txt.
Description
Jonas Paludo and colleagues evaluate how well a cancer drug's liquid suspension is absorbed and whether it can be delivered through feeding tubes. Their 2025 study concerns ibrutinib, used for several blood cancers and graft-versus-host disease.
Patients who struggle to swallow capsules or tablets need alternative ways to take the drug. In healthy volunteers, the suspension's absorption matched capsules at the same daily dose under fasting conditions. Dose-adjusted values were similar across formulations in patient studies too. Laboratory mock administrations through syringes and two tube types recovered nearly the full intended dose in every case. Impurities, particle size, and holding time were also checked for each delivery route.
Catalog record
| CREATOR | Jonas Paludo, Lisa Nodzon, Xavier Woot de Trixhe, Michelle Pacia, Heena Mavani, Harisha Atluri, Thomas J Huemann, Jessica Shelly, Yemin Liu, Shayna Sarosiek |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |